Kainomyx — Antimalarial Drug (2021)

[Other Scientific Research Areas] Open Philanthropy recommended an investment of $4,000,000 in Kainomyx to develop and produce new drugs to treat malaria and other parasitic diseases, such as cryptosporidiosis and toxoplasmosis. If effective, the new drugs would act by inhibiting cytoskeletal proteins in malarial and other parasites. Our science team believes that there is a need for new antimalarial drugs due to increasing resistance to existing treatments. This follows our May 2020 investment and falls within our work on scientific research, specifically within our interest in advancing human health and wellbeing.